**Background of NGEF Antibody**
Neuronal Guanine Nucleotide Exchange Factor (NGEF), also known as ARHGEF27 or PLEKHG5. belongs to the RhoGEF family, which regulates Rho GTPases—key mediators of cytoskeletal reorganization, cell migration, and signaling pathways. NGEF is predominantly expressed in the nervous system, where it interacts with Rho GTPases like RhoA and Cdc42 to modulate neuronal morphology, axon guidance, and synaptic plasticity. Studies highlight its role in neuronal development, particularly in dendritic spine formation and neurite outgrowth, processes critical for neural network establishment and function.
Dysregulation of NGEF has been implicated in neurological disorders. For instance, mutations in the *PLEKHG5* gene are linked to motor neuron diseases, including autosomal recessive lower motor neuron disease (LMND) and Charcot-Marie-Tooth neuropathy. Altered NGEF expression is also observed in neurodegenerative conditions like Alzheimer’s disease, potentially influencing amyloid-beta-induced synaptic toxicity. Additionally, NGEF may contribute to psychiatric disorders through its impact on synaptic signaling.
NGEF antibodies are essential tools for detecting NGEF protein levels, localization, and activity in research. They enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, aiding in the exploration of NGEF’s mechanistic roles in health and disease. These antibodies also support drug discovery efforts by identifying NGEF as a potential therapeutic target for neurological conditions. Overall, NGEF antibodies bridge molecular insights with clinical applications, advancing understanding of neural pathophysiology.